Mukesh Verma, Ph.D.
Branch Chief, Methods and Technologies Branch

Address:
Epidemiology and Genomics Research Program
Division of Cancer Control and Population Sciences
National Cancer Institute
National Institutes of Health
9609 Medical Center Drive, Rm. 4E102, MSC 9763
Bethesda, MD 20892
(For express delivery, use Rockville, MD 20850)

Degrees

  • Ph.D. - Host-virus Interaction
    Banaras Hindu University
  • M.Sc. - Biochemistry (Major) and Microbiology (Minor)
    Pantnagar University
  • B.Sc. - Biological Sciences
    Meerut University

Interest Areas

  • Biomarkers
  • Epigenetics and epidemiology
  • Molecular epidemiology technologies
  • Mitochondria
  • Metabolomics
  • Microbiome

Biography

Dr. Verma is Chief of the Epidemiology and Genomics Research Program's (EGRP) Methods and Technologies Branch (MTB), and oversees its research portfolio and initiatives that focus on methods to address epidemiologic data collection, study design and analysis, and to modify technological approaches developed in the context of other research endeavors for use as biomarkers and methods to understand cancer susceptibility.

He is responsible for stimulating research in implication of omics approaches to understand cancer etiology. He represents NCI in Common Fund Programs on (1) Epigenomics, (2) Metabolomics, (3) Molecular Transducers of Physical Activity, and (4) congressionally-mandated program on Environmental Influences on Child Health Outcome (ECHO). Since joining the NCI, he sought to champion the visibility of and investment in cancer epigenetics research both within the Institute and across other federal and non-governmental agencies and to raise public awareness about controlling cancer.

Dr. Verma is the Program Director and contact person for the initiative “Exploratory Grants in Cancer Epidemiology and Genomics Research” (PA-16-175). He is also the Co-Program Director on “’High’ or ‘Medium’ Priority AIDS Research on Non-AIDS-defining or AIDS-defining Cancers” (PA-16-426); “Social Epigenomics Research Focused on Minority Health and Health Disparities” (PAR-16-355); “Assay Validation for High Quality Markers for NCI-Supported Clinical Trials”(PAR-15-095); and “Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Coordination and Data Management Center (CSCPDPC-CDMC)” (RFA-DK-14-028).

Dr. Verma joined EGRP as a Program Director in 2004. In 2005, he was appointed Acting Chief of EGRP's former Analytic Epidemiology Research Branch (AERB). When EGRP reorganized in 2007, he was appointed Acting Chief of MTB and of the former Host Susceptibility Factors Branch (HSFB), for which he served as Acting Chief through 2008. Before joining EGRP, he was a Program Director in NCI's Division of Cancer Prevention (DCP), where he worked in the areas of biomarkers, early detection, risk assessment, and prevention. He also was Coordinator of DCP's Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs. He was on the faculty in the Biochemistry Department of Georgetown University before joining NIH.

Publications

Verma M, Kumar V. Epigenetic biomarkers in colorectal cancer. Mol Diagn Ther. 2017 Apr;21(2):153-165.

Verma M. Mechanistic and technical challenges in studying the human microbiome and cancer epidemiology. Technol Cancer Res Treat. 2017 Apr 27;16(2):150-158.

Shea A, Harish V, Afzal Z, Chijioke J, Kedir H, Dusmatova S, Roy A, Ramalinga M, Harris B, Blancato J, Verma M, Kumar D. MicroRNAs in glioblastoma multiforme pathogenesis and therapeutics. Cancer Med. 2016 Aug;5(8):1917-46.

Verma M. Genome-wide association studies and epigenome-wide association studies go together in cancer control. Future Oncol. 2016 Jul;12(13):1645-64.

Banerjee H, Verma M. Intraoperative brain cancer detection with Raman spectroscopy in humans. Ann Transl Med. 2016 Feb;4(4):68.

Verma M, Barh D, ed. Progress and challenges in precision medicineExternal Web Site Policy. New York, NY: Academic Press; 2016.

Verma M, Badve S. Epigenetic mechanism in breast cancer. In: Badve S, Gökmen-Polar Y, eds. Molecular Pathology of Breast CancerExternal Web Site Policy. Cham, CH: Springer International Publishing; 2016.

Verma M. The role of epigenomics in the study of cancer biomarkers in the development of diagnostic tools. Adv Exp Med Biol. 2015;867:59-80.

Verma M. The role of epigenomics in the study of cancer biomarkers and in the development of diagnostic tools. In: Scatena R, ed. Advances in Cancer BiomarkersExternal Web Site Policy. New York, NY: Springer Press; 2015.

Vedham V, Verma M, Mahabir S. Early-life exposure to infectious agents and later cancer development. Cancer Med. 2015 Dec;4(12):1908-22.

Chai RC, Lambie D, Verma M, Punyadeera C. Current trends in the etiology and diagnosis of HPV-related head and neck cancers. Cancer Med. 2015 Apr;4(4):596-607.

Hebert E, Rao LD, Verma M. Microbiome analysis: trends in cancer epidemiology, challenges and opportunitiesExternal Web Site Policy. Int J Cancer Res Mol Mech. 2015 Apr;1:1-5.

Verma M, Lam TK, Hebert E, Divi RL. Extracellular vesicles: potential applications in cancer diagnosis, prognosis, and epidemiology. BMC Clin Pathol. 2015 Apr;15:6.

Verma M, Banerjee HN. Metabolomics approaches in cancer epidemiologyExternal Web Site Policy. Diseases. 2015;3:167-175

Verma M. The role of epigenomics in the study of cancer biomarkers in the development of diagnostic tools. Adv Exp Med Biol. 2015;867:59-80.

Verma M. Epigenetic regulation of HIV, AIDS, and AIDS-related malignancies. Methods Mol Biol. 2015;1238:381-403.

Vedham V, Verma M. Cancer-associated infectious agents and epigenetic regulation. Methods Mol Biol. 2015;1238:333-54.

Litzelman K, Verma M. Epigenetic regulation in biopsychosocial pathways. Methods Mol Biol. 2015;1238:549-67.

Verma M. Toxicoepigenomics and cancer: implications for screening. Methods Mol Biol. 2015;1238:355-67.

Return to Top